| Project/Area Number |
26670606
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
OKA Masaaki 山口大学, その他部局等, 学長 (70144946)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIMURA Kiyoshi 国立がん研究センター, 先端医療開発センター・免疫療法開発分野, 分野長 (30346564)
TSUNEDOMI Ryouichi 山口大学, 大学院医学系研究科, 助教 (10420514)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 肝細胞癌 / ワクチン療法 / HSP70 / エピトープペプチド / 免疫療法 |
|---|
| Outline of Final Research Achievements |
We identified the Heat Shock Protein (HSP) 70 as a specific antigen of hepatocellular carcinoma. Furthermore, the phase I study of HSP70-mRNA introduced dendritic cells therapy showed the safety and efficacy. In this study, we tried to identify the HSP70 peptide sequence, which can induce the anti-tumor response, in order to the development of useful peptide vaccine therapy for cancer. Candidate HSP70 peptides predicted as multi-HLA binding potency were confirmed by ELISpot assay and ELISA for IFN-gamma production. The safty of the peptides were examined in rats and dogs. We started a clinical trial of first in Human HSP70 peptide immunetherapy for several cancers.
|
